Last reviewed · How we verify

Rybrevant — Competitive Intelligence Brief

Rybrevant (AMIVANTAMAB) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed EGFR, MET Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Rybrevant (AMIVANTAMAB) — Johnson & Johnson. Amivantamab-vmjw targets EGFR and MET, disrupting their signaling and enhancing immune cell-mediated destruction of tumor cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rybrevant TARGET AMIVANTAMAB Johnson & Johnson marketed EGFR, MET 2021-01-01

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rybrevant — Competitive Intelligence Brief. https://druglandscape.com/ci/amivantamab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: